PURE Bioscience Reports Increased Q3 Loss, Raises $1M in Dilutive Private Placement, and Authorizes 92% More Shares

summarizeSummary

PURE Bioscience reported an increased Q3 net loss and reiterated going concern doubts, while securing $1.0 million in dilutive financing and authorizing a massive increase in potential share issuance.

check_boxKey Events · Financing and Capital Events · PURE

• Going Concern Warning

  The company reported an increased net loss of $624,000 for Q3 and a stockholders' deficiency of $5.84 million, leading to substantial doubt about its ability to continue as a going concern.

• Massive Potential Dilution

  Shareholders approved increasing authorized common stock by 50 million shares to 250 million, effective May 27, 2026. If all authorized shares were issued, dilution would be 92.28%.

• Dilutive Private Placement

  The company completed a $1.0 million private placement on April 30, 2026, issuing 18.13 million shares at $0.0553 per share, a discount to the current market price. Board members Tom Y. Lee and Ivan Chen invested $700,000 and $27,650, respectively.

• New Related-Party Debt

  PURE Bioscience secured an additional $970,000 in convertible notes from a board member, part of a larger $2.0 million offering, further increasing its reliance on related-party financing. Total convertible notes and accrued interest stand at $6.5 million.

auto_awesomeAnalysis · PURE · Industrial Applications And Services

This 10-Q details PURE Bioscience's continued financial distress, including an increased net loss and a substantial doubt about its ability to continue as a going concern. The company is heavily reliant on dilutive financing, having recently completed a $1.0 million private placement at a discount and secured new convertible notes from a board member. Furthermore, shareholders approved a significant increase in authorized common stock, allowing for potential future dilution of over 90%. The CEO is also set to retire, with the President taking over.